Localized cutaneous nontender nodules appeared on the back of a 52-year-old Japanese woman. Skin biopsy revealed atypical large T-lymphocytes infiltrating the dermis. CD30 staining was negative in tumor cells. The diagnosis was CD30-negative cutaneous large T cell lymphoma. There was no evidence of peripheral lymphadenopathy or bone marrow involvement. Six cycles of induction chemotherapy were administered and a complete clinical remission (CCR) was attained. Local irradiation was not given. As the clinical course of CD30-negative cutaneous large T cell lymphoma is recurrent and often incurable with conventional chemoradiotherapy, she received high-dose chemotherapy without total body irradiation (TBI) followed by unpurged autologous peripheral blood stem cell transplantation (APBSCT). A relapse in the skin followed 40 days after APBSCT, but tumor cells transformed into a CD30-positive anaplastic large cell lymphoma (ALCL). We question the need for TBI in conditioning and for purged stem cells for APBSCT in patients with high risk cutaneous lymphomas. Keywords: CD30-negative cutaneous large T cell lymphoma; autologous peripheral blood stem cell transplantation (APBSCT); histological transformation Cutaneous T cell lymphoma (CTCL) other than mycosis fungoides (MF) represents a rare and heterogeneous group of lymphomas; the clinical behavior has seldom been described. [1] [2] [3] [4] In 1997, the European Organization for Research and Treatment of Cancer (EORTC) reported a new classification for primary cutaneous lymphoma. 5 In their report, CTCL were subdivided into two categories: indolent and aggressive forms according to clinical behavior. CD30-negative large T cell lymphoma, classified as one of the aggressive CTCL, accounted for 5% (36/626) of all primary cutaneous lymphomas and the estimated 5-year survival was 15%.
Cutaneous T cell lymphoma (CTCL) other than mycosis fungoides (MF) represents a rare and heterogeneous group of lymphomas; the clinical behavior has seldom been described. [1] [2] [3] [4] In 1997, the European Organization for Research and Treatment of Cancer (EORTC) reported a new classification for primary cutaneous lymphoma. 5 In their report, CTCL were subdivided into two categories: indolent and aggressive forms according to clinical behavior. CD30-negative large T cell lymphoma, classified Correspondence: Dr K Sawada, Department of Medicine II, Hokkaido University School of Medicine, N-15, W-7, Kita-ku, Sapporo 060-8638, Japan Received 26 May 1998; accepted 23 July 1998 as one of the aggressive CTCL, accounted for 5% (36/626) of all primary cutaneous lymphomas and the estimated 5-year survival was 15%. 1, 5 An effective and curative therapeutic strategy for CTCL with this histology has not been established. We describe the clinical features in a woman with CD30-negative large T cell lymphoma and the early recurrence after high-dose chemotherapy with APBSCT.
Case report
A previously healthy 52-year-old Japanese woman presented with nontender localized cutaneous nodules on her back in August 1997. Systemic B symptoms were nil and all vital signs were normal. The major finding was several smooth cutaneous nodules, without ulceration, ranging in size from 1 to 3 cm on her left back, and irregularly outlined erythema on her right back. Physical examination and CT scan of the chest and abdomen revealed no evidence of peripheral lymphadenopathy or hepatosplenomegaly. All laboratory values were normal, including serum lactate dehydrogenase (LDH) and soluble IL-2 receptor. Serologic studies were negative for human T lymphocytotropic virus-I (HTLV-I) and human immunodeficiency virus (HIV). Bone marrow aspiration and biopsy revealed no involvement by atypical lymphocytes.
Skin biopsy of a nodule on her left back revealed an atypical large lymphocyte infiltration of the entire dermis, with epidermotropism ( Figure 1 ). Immunohistochemical studies showed that the atypical lymphocytes were positive for CD3, CD4, CD8 and negative for CD30. Clonal rearrangement of TCR C␤1 was evident in the Southern blot analysis. Cytogenetic analysis was not done. Clinical and histological findings led to a diagnosis of CD30-negative large T cell lymphoma in the EORTC classification. 5 Her clinical stage was determined as IE according to the Ann Arbor staging system. 6 However, we considered that she was at a high risk for a recurrence if conventional chemotherapy and local radiotherapy alone were given, as based on our experiences and related documentation. 1, 2, 5 We decided on intensive treatment with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (APBSCT), as first line therapy. Prior to the start of treatment, she gave informed consent as approved by the Committee of Hokkaido University School of Medicine for the Protection of Human Subjects.
For induction, three cycles of CHOP 7, 8 were administered and the tumors disappeared rapidly. Complete remission was verified by skin biopsy, and the bone marrow remained free of lymphoma. Next, she was given three cycles of etoposide 500 mg/m 2 , ifosfamide 4000 mg/m 2 and cispatin 50 mg/m 2 , on day 1 i.v. (VIP regimen). 9 After the first cycle of VIP, peripheral blood stem cells (PBSC) were collected. Clonal rearrangement of TCR C␤-1 was not detected in PBSC by Southern blot analysis. After six cycles of conventional chemotherapy, APBSCT was undertaken. Conditioning prior to APBSCT was with 200 mg/m 2 ranimustine (MCNU) on days −8 and −3, 300 mg/m 2 carboplatin (CBDCA) on days −7 to −4, 500 mg/m 2 etoposide (VP-16) on days −6 to −4, and 50 mg/kg cyclophosphamide on days −3 and −2 (MCVC regimen). 10 This conditioning regimen commenced on 13 January 1998, and unpurged PBSC were re-infused on day 0. The number of cells infused was 2.62 × 10 6 /kg CD34 + cells and 6.54 × 10 5 /kg CFU-GM. Following PBSCT, the time required to recover neutrophils to over 0.5 × 10 9 /l and platelets to over 50 × 10 9 /l was 8 and 11 days, respectively. There was no evidence of malignancy until the end of February, 1998, 40 days after completion of APBSCT. Small, red nodules with ulceration on her neck, forehead and extremities soon became evident. Skin biopsy showed numerous inflammatory cells (neutorophils and eosinophils) and atypical large lymphocytes, with round, oval-shaped nuclei, prominent nucleoli, and abundant cytoplasm (Figure 2 ). CD30 was expressed by the majority of neoplastic cells (Figure 3 ). Clonal rearrangement of TCR C␤1 was evident on Southern blot analysis and the band was identical to that seen in the original one. There was no evidence of extracutaneous tumor. Recurrence of CTCL with histological transformation 11,12 was confirmed and she was treated with whole body electron beam radiotherapy and low-dose etoposide as salvage therapy. 13 At present she is in remission.
Discussion
In 1997, the EORTC classified primary cutaneous lymphomas based on evidence that primary cutaneous lymphomas and primary nodal lymphomas, albeit morphologically identical, should be considered as distinct groups of diseases. 5 Since the frequency of primary cutaneous lymphomas other than MF in the literature is about 5%, [14] [15] [16] the number of reports of treatment for such lymphomas is scanty. Patients with stage IE cutaneous lymphomas have been treated with local radiotherapy alone, or sometimes combined with systemic chemotherapy, and those with stage IV have been given systemic chemotherapy.
1,2 However, relapse is frequent and often fatal. In nodal lymphomas, high-dose chemoradiotherapy followed by autologous stem cell transplantation can be effective in cases of relapse and some reports suggest that this procedure may be considered as part of first-line therapy for selected patients with a poor prognosis. 17 Established prognostic factors for primary cutaneous lymphomas are histopathology and clinical stage. 2, 5 The clinical stage of our patient was IE but she had the histology of a CD30-negative large T cell lymphoma, which has a poor prognosis. The estimated 5-year survival of 36 patients was only 15%. 1 In addition, the best initial therapy for patients with stage IE intermediate/high-grade lymphomas remains controversial. A high incidence of relapse has been reported (69% within 2 years) in such patients given radiotherapy alone. 2 Moreover, 50% of patients who experienced a relapse died of lymphoma. For this reason, we treated our patient with high-dose chemotherapy as consolidation in first CCR, even though she was grouped into a low-risk category by the international prognostic index. 18 Failure of APBSCT can occur due to presence of malignant cells in the PBSC, or inadequacy of conditioning therapy to eradicate malignant cells. 19 We found only two reports of high-dose chemotherapy or chemoradiotherapy for primary cutaneous lymphoma, other than MF. Moreau et al 20 reported good results for stage IV patients treated with a TBI-containing regimen. All four patients are alive in CCR with a long follow-up. They recommended TBI in a homogenized dose for skin application. Zeitoun et al 21 reported data on seven patients with high-grade or disseminated cutaneous lymphomas; four patients were treated with a TBI-containing regimen and three with high-dose chemotherapy alone. There was prolonged, complete remission in patients given TBI and early recurrence in those given chemotherapy alone, as seen in our patient. Unpurged stem cells were used in both cases. These findings suggest that intensive therapy with a conditioning regimen including TBI, may be more effective than chemotherapy alone. For our patient, PBSC were harvested in CCR and clonal rearrangement was not detected in PBSC by Southern blot analysis. However, Muche et al 22 found a high frequency of identical clonal T cells in peripheral blood and skin of CTCL patients by a highly sensitive polymerase chain reaction (PCR) assay, including early stages of CTCL. Their findings show that CTCL is a systemic and monoclonal disease right from the beginning, even if extracutaneous spread is not yet clinically apparent. Under these conditions, APBSCT with CD34 + selection may decrease the likelihood of contamination by malignant cells. 23, 24 Recent studies have found that primary cutaneous lymphomas often have highly characteristic clinical and histologic features and prognosis. The most effective initial treatment for cutaneous lymphomas, especially for those with a poor prognosis as in our patient, remains to be determined. It is difficult to assess the necessity and role for high-dose chemotherapy or chemoradiotherapy followed by APBSCT from such a small number of cases. However, we found that high-dose chemotherapy with APBSCT alone was inadequate to eradicate the malignant cells. A TBIcontaining conditioning regimen or CD34
+ selected transplantation may possibly lead to a better outcome in APBSCT for high risk primary cutaneous lymphomas, such as CD30 negative large T cell lymphomas.
